ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Professional Societies: ASCO Develops Cancer Genetics Curriculum

December 18, 1998

Study Seeks Newly Diagnosed Prostate Cancer Patients

March 26, 2010

Youth Smoking Linked To Exposure In Movies

December 30, 2005

Farber Grant Probe Misses Real Story

July 8, 1977

Policy Of 5,000 Grants Meant As Floor, Not Ceiling, Former White House Advisor Insists

March 8, 1985

Continuing Resolution Averts Shutdown; Locks in Sequestration Cuts for NIH, NCI

March 22, 2013